Please login to the form below

Not currently logged in
Email:
Password:

PPD to create 400 jobs in Scottish base expansion

Pharmaceutical Product Development says it will double its workforce in an expansion of its Bellshill base in Scotland

Pharmaceutical Product Development (PDD), a multinational pharmaceutical and biotech research company, has revealed it shall double its workforce in an expansion of its Bellshill base in Scotland.

PPD posted a 29 per cent increase in FY06 income to make GBP 80m (USD 162.4m) and said at the time that it would create the jobs over three years as part of a GBP 15m (USD 30.5m) expansion of its base at the Strathclyde Business Park. PPD's present expansion follows the companyís recent announcement of a 24.6 per cent increase in its net income for Q2 FY07 at GBP 30.5m (USD 62m).

PDD is a multinational organisation that employs 9,700 workers in 28 countries and made the announcement after receiving a second Regional Selective Assistance (RSA) grant in as many years. Regional public spending on the company now stands at GBP 7.5m (USD 15.2m).

PDDís Bellshill base has 350 workers there now that conduct clinical medicine trials and offer data management services. The latest expansion is being supported by an RSA grant from the Scottish Executive of GBP 4.5m (USD 9,1m), or GBP 11,500 (USD 23,359) per person employed.

The new jobs will include positions at data development, biostatistics and clinical trial management and monitoring. PDD received a GBP 3m (USD 6.1m) RSA grant from the Scottish Executive two years earlier after a previous expansion, which then resulted in 100 new jobs.

31st July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics